Results for the Quarter and Year ended 31 March 2026
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.9 pts more than Nifty Microcap 250 and 10.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Viyash Scientific reported strong consolidated results for FY2026 with revenue from operations growing 13.7% to ₹34,203.10 million (PY restated: ₹30,068.40 million). Profit after tax surged over 13x to ₹2,246.50 million (PY: ₹157.70 million restated), driven significantly by the amalgamation of Viyash Life Sciences Private Limited and its subsidiaries effective December 2025, accounted under the pooling of interest method. Prior period figures have been restated to reflect the combined entity from April 2024. The company posted exceptional items of ₹442.10 million (standalone) including a gain on sale of land at Visakhapatnam facility. Basic EPS on consolidated basis improved to ₹4.09 (PY restated: ₹0.54). The board also approved a large employee stock option scheme (1.31 crore options) and adopted new Articles of Association. No dividend was recommended.
The massive PAT growth on restated consolidated numbers is largely attributable to the amalgamation; underlying organic performance also improved. However, investors should note the prior periods are not comparable to historical reported figures due to the restatement and business combination. The large ESOP grant may dilute earnings per share going forward.